Metoclopramide Hydrochloride

ALPHARETTA, Ga., Jan. 27, 2026 /PRNewswire/ -- Avion Pharmaceuticals, an Alora Pharmaceuticals subsidiary company focused on advancing treatment for Parkinson's disease, is proud to announce the findings from a recently published study examining the real-world practice of splitting carbidopa/levodopa tablets. The article, Practices and Perceptions Around Splitting of Carbidopa/Levodopa Tablets: A Survey of Patients and Neurologists, appears in Neurodegenerative Disease Management and reports that people living with Parkinson's disease often split immediate-release carbidopa/levodopa tablets to manage motor symptoms, a practice that becomes more common, burdensome, and imprecise as the disease progresses. The study, led by Drs. Ramon L. Rodriguez, Stuart H. Isaacson, Yasar Torres-Yaghi, Rajesh Pahwa, and Ahmad Al-Sabbagh, highlights ongoing challenges related to dosing precision, treatment complexity, and quality of life for people living with Parkinson's disease. To better understand these challenges, researchers conducted surveys among 101 people living with Parkinson's disease and caregivers, as well as 120 neurologists, including movement disorder specialists. Across respondents, motor symptoms were reported to have a substantial impact on quality of life, particularly in the later stages of the disease. Among surveyed patients with longer disease duration, more advanced disease, and greater difficulty controlling motor fluctuations, pill splitting was more commonly reported. Of those surveyed that reported splitting pills in half, only 27% find pill splitting easy and of those surveyed who fragmented their pills further beyond a half, just 18% find it accurate.1 "These survey findings reinforce what we hear consistently from patients and clinicians - that dosing flexibility and precision become increasingly important as Parkinson's disease progresses," said Art Deas, Chief Executive Officer of Alora Pharmaceuticals. "DHIVY was developed to address this challenge. It is the first and only functionally scored immediate release carbidopa/levodopa tablet, designed to allow a single tablet to be divided into smaller, more precise segments that are easy to snap, supporting individualized dosing without the need for traditional pill splitting."2-4 Neurologists participating in the survey also reported growing dissatisfaction with available treatment options as Parkinson's disease progresses. Physicians estimated that approximately 45% of their patients split carbidopa/levodopa tablets based on medical recommendation, while nearly 22% do so independently without physician guidance. Overall, the findings underscore the importance of continued collaboration among patients, caregivers, and healthcare providers to address evolving treatment needs and help reduce treatment burden as Parkinson's disease advances. About DHIVY DHIVY® (carbidopa and levodopa) tablets are indicated for the treatment of Parkinson's disease. DHIVY is a functionally scored tablet designed to allow division into smaller dose segments. Patients should take DHIVY exactly as prescribed.2 See ISI below. About Alora Pharmaceuticals Alora Pharmaceuticals is dedicated to improving the lives of individuals with neurological disorders through innovative therapeutic solutions and patient-centered support. Headquartered in Alpharetta, GA, the company focuses on advancing treatments that make real differences in daily care. About the Study The full study, "Practices and perceptions around splitting of carbidopa/levodopa tablets: a survey of patients and neurologists," is available in Neurodegenerative Disease Management (DOI: 10.1080/17582024.2025.2577054). © 2026 Alora Pharmaceuticals, LLC. All rights reserved. DHIVY® is a registered trademark of Avion Pharmaceuticals, LLC. References: 1. Rodriguez R., Isaacson S., Torres-Yaghi Y, Pahwa - full-view-affiliation-4 R. Holecek D, Al-Sabbagh A. Practices and perceptions around splitting of carbidopa/levodopa tablets: a survey of patients and neurologists. Neurodegenerative Disease Management, 2025 Dec 3:1-7. doi: 10.1080/17582024.2025.2577054 2. DHIVY. Package insert. Avion Pharmaceuticals, LLC; 2022. 3. Beach D. Accu-Break's innovative tablet technology – 2016 advancements. ONdrugDelivery Magazine. 2016;69:39-40. 4. Center for Drug Evaluation and Research, Food and Drug Administration. Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation. US Department of Health and Human Services; 2013. IMPORTANT SAFETY INFORMATION & INDICATION DHIVY is contraindicated in patients Currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine, linezolid, and tranylcypromine) or have recently (within 2 weeks) taken a nonselective MAO inhibitor. Hypertension can occur if these drugs are used concurrently. With known hypersensitivity to any component of DHIVY. Taking DHIVY may result in falling asleep while engaged in normal activities, even without warning and as late as 1 year or later after starting DHIVY. This may affect your ability to drive or operate machinery, resulting in accidents. Do not do anything that requires alertness until you know how DHIVY affects you. Tell your healthcare provider about any sleep medicines you take or if you have a sleep disorder and discuss any episodes of drowsiness or sleepiness you experience while taking DHIVY. Talk to your healthcare provider before you change the dose or stop taking DHIVY, as this may result in serious side effects. Call your healthcare provider immediately if you develop withdrawal symptoms such as fever, confusion, or severe muscle stiffness. Tell your healthcare provider if you have any heart conditions, especially if you have had a heart attack or irregular heartbeats. Your heart function should be monitored during the time period your DHIVY dose is first adjusted. Treatment with DHIVY may cause hallucinations or abnormal thoughts and behaviors. Be sure to tell your healthcare provider if you experience excessive suspicion; seeing, hearing, or feeling things that are not real; confusion; agitation; aggressive behavior; and disorganized thinking. Treatment with DHIVY may also cause intense urges to gamble, increased sexual urges, intense urges to spend money, binge eating, and other intense urges, as well as the inability to control those urges. Uncontrolled sudden movements of the face, arms, legs, or trunk may appear or get worse during treatment with DHIVY. This may mean your dosage of DHIVY or other Parkinson's medications needs to be adjusted. Tell your healthcare provider if you have ever had a peptic ulcer or glaucoma, as treatment with DHIVY may worsen these conditions. DHIVY also may cause abnormal blood or urine test results. Some patients taking DHIVY may experience depression or suicidal thoughts. Tell your healthcare provider if you have thoughts of suicide. The most common side effects that may appear with DHIVY include uncontrolled sudden movements and nausea. Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using DHIVY with certain other medicines, including MAO inhibitors, isoniazid, iron supplements, medicines for high blood pressure or those that increase or decrease dopamine levels, or metoclopramide, may cause serious side effects. Notify your healthcare provider if you become pregnant or intend to become pregnant during DHIVY therapy or if you intend to breastfeed or are breastfeeding an infant. INDICATION DHIVY is a prescription medication that contains a combination of carbidopa and levodopa for the treatment of Parkinson's disease, Parkinson's disease caused by infection or inflammation of the brain, or Parkinson's disease–like symptoms that may result from carbon monoxide or manganese poisoning. You may report side effects to Avion Pharmaceuticals, LLC at 1-888-612-8466 or to the FDA at 1-800-FDA-1088. Please click here for full Prescribing Information. NP-4069-v1 (v1.2) SOURCE Alora Pharmaceuticals, LLC 21% more press release views with Request a Demo

SAN DIEGO, Jan. 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is a next-generation, selective inhibitor of the vesicular monoamine transporter 2 (VMAT2). Building on nearly 20 years of deep scientific expertise and experience in VMAT2 inhibition, Neurocrine designed NBI-1065890 to potentially deliver a differentiated profile, including the possibility of longer-acting options for the treatment of TD. "NBI-'890 is an internally discovered molecule with distinct physical and chemical properties that may allow it to benefit a broader range of patients with tardive dyskinesia," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "Advancing this program to a Phase 2 clinical study is key to our strategy to define the future of VMAT2 biology and deliver lasting impact for patients." This Phase 2, randomized, double-blind, placebo-controlled study will enroll approximately 100 adult subjects with TD and will assess the efficacy, safety, and tolerability of NBI-1065890 compared with placebo. The primary efficacy endpoint is change from baseline in the Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score (sum of Items 1–7) at Week 8. Neurocrine successfully developed and received U.S. Food and Drug Administration approval in 2017 for valbenazine, a selective VMAT2 inhibitor, for use as the first drug ever developed for the treatment of tardive dyskinesia. In 2023, the company received FDA approval for valbenazine as a treatment for chorea associated with Huntington's disease. For more information about the Phase 2 study (NBI-1065890-TD2033), visit ClinicalTrials.gov. About Tardive Dyskinesia Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrolled, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with taking certain kinds of mental health medicines (antipsychotics) that help control dopamine receptors in the brain. Taking antipsychotics commonly prescribed to treat mental illnesses such as major depressive disorder, bipolar disorder, schizophrenia and schizoaffective disorder and other prescription medicines (metoclopramide and prochlorperazine) used to treat gastrointestinal disorders are associated with TD. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms of TD can be mild to severe and are often persistent and irreversible. TD is estimated to affect at least 800,000 adults in the U.S. About NBI-1065890 NBI-1065890, discovered and developed internally at Neurocrine, is a potent, selective and orally bioavailable inhibitor of vesicular monoamine transporter 2 (VMAT2) in clinical development for the treatment of tardive dyskinesia (TD). Inhibition of VMAT2 is expected to provide therapeutic benefit in TD, other hyperkinetic movement disorders, and potentially other CNS disorders where dopaminergic signaling is dysregulated. About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie) The NEUROCRINE BIOSCIENCES logo, NEUROCRINE and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the efficacy and therapeutic potential of NBI-1065890. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks that clinical development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that regulatory submissions for our product candidates may not occur or be submitted in a timely manner; our future financial and operating performance; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with U.S. federal or state legislative or regulatory and/or policy efforts which may result in, among other things, an adverse impact on our revenues or potential revenue; risks associated with potential generic entrants for our products; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's annual report on Form 10-K for the year ended September 30, 2025. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. © 2026 Neurocrine Biosciences, Inc. All Rights Reserved. SOURCE Neurocrine Biosciences, Inc. 21% more press release views with Request a Demo